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Abstract
Introduction: The aim of the paper was to evaluate the compliance in patients who have undergone orthotopic liver 
transplantation (OLT).
Materials and methods: A voluntary anonymous survey was conducted among liver transplant recipients. The control 
group included patients with chronic non-infectious diseases requiring persistent treatment. The questionnaire “The 
level of Compliance” designed by R.V. Kadyrov was used.
Results and discussion: The following compliance levels were identified in liver transplant recipients: the general 
level – 95.8±9.4; the social level – 30.4±4.2; the emotional level – 33.3±3.7; the behavioral level – 32.0±3.8. The com-
pliance levels of the control group were significantly lower compared to the values of group 1, respectively: the general 
level – by 9%, the social level – by 5.6%, the emotional level – by 10.3% and the behavioral level – by 11.9%. The 
general compliance level of the recipients under 50 years old reached 93.5±6.8; the social compliance level – 28.9±3.9; 
the emotional compliance level – 33.6±2.9 and the behavioral compliance level –31.0±2.2. 
Conclusions: Liver transplant patients have higher levels of general, behavioral and emotional compliance compared 
to patients with chronic diseases. Neither gender nor age differences were identified in any types of compliance.
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Introduction
The compliance to therapy according to the definition of 
the World Health Organization is defined as an extent to 
which a patient follows treatment recommendations, in-
cluding timely medications intake, diet, changes in the 
lifestyle and regular visits to a doctor (World Health Or-
ganization – WHO 2001).
A low level of compliance is a worldwide problem 
as patients’ compliance to treatment recommendations 
significantly affects the outcome of almost all diseases. 
The compliance to treatment of diseases with high risk 
of disability and mortality has been actively studied over 
the past decades. In the register and observational stu-
dies of patients with cardiovascular, broncho-pulmonary, 
endocrinological, gastroenterological, rheumatological 
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diseases, the low levels of compliance to vital drugs were 
recorded (Dobrovol’skaya et al. 2018, Krivoshapova et al. 
2018, Machilskaya 2016, Mashkunova et al. 2018, Ma-
yorova and Khrushcheva 2018, Olevskaya et al. 2018).
Due to the dramatically high medical and social costs 
of transplant care and the subsequent vital immunosup-
pressive therapy, the compliance of transplant recipients 
is of great interest to both practicing doctors and resear-
chers – healthcare providers.
The compliance to an effective immunosuppressive re-
gimen was defined in the early works of S. De Geest et 
al. (De Geest et al. 1999) as a vital behaviur to prevent 
the post-transplant rejection. The researchers found that 
non-compliance to drug treatment led to an increase in 
late acute transplant rejection in 3% of cases in patients 
who had undergone heart transplantation (De Geest et al. 
1998). In kidney transplant recipients, non-compliance to 
drug therapy is associated with a prognosis worsening, 
which may result in an acute and chronic transplant rejec-
tion, functional depression leading to a dialysis or morta-
lity (De Geest et al. 1995, Nevins et al. 2001, Shoskes et 
al. 1997). The return to dialysis after transplant rejection 
increases the risk of mortality by 78% compared to the 
patients on dialysis from the waiting list of (Rao et al. 
2007). The studies of compliance in liver transplant re-
cipients were conducted in a number of foreign clinical 
centers (Berlakovich et al. 2000, Drent et al. 2005, O’Car-
roll et al. 2006, Schweizer et al. 1990, Stilley et al. 2010). 
The majority of the studies involved a small number of 
patients and evaluated compliance by different methods, 
which makes it difficult to compare the results. Having 
analyzed the scientific literature of both Medline database 
and the largest Russian electronic library of scientific pu-
blications (e-library) over the last 15 years, no study has 
been found of the compliance in liver transplant recipients 
in Russian transplant centers.
The aim of the paper was to evaluate the complian-
ce in patients who underwent OLT in the “Scientific and 
Research Institute – S.V. Ochapovsky Regional Clinical 
Hospital One”.
Materials and methods
A voluntary anonymous survey was conducted among 
liver transplant recipients (group 1) operated on at the 
state budgetary healthcare institution – “Scientific and 
Research Institute – S.V. Ochapovsky Regional Clinical 
Hospital One” of the Ministry of Healthcare of Krasno-
dar region. The study was approved by the local ethics 
committee. The questionnaire “The Level of Complian-
ce” designed by R.V. Kadyrov was used in the research 
(Kadyrov et al. 2014).
The questionnaire consists of the two parts with 66 
statements each – for healthy people and for those with 
chronic diseases. The control group (group 2) involved 
patients with chronic noncommunicable diseases re-
quiring persistent treatment. Three types of compliance 
behavior – social, behavioral and emotional – were as-
sessed. The following indicators of compliance behavior 
were used: subtle – from 0 to 15 score points; moderate – 
from 16 to 29 score points, and significant – from 30 to 40 
score points. The overall compliance level is represented 
by the sum of the score points of all compliance behavior 
indicators and is interpreted as follows: a low compliance 
level – from 0 to 40 score points, an average compliance 
level – from 41 to 80 score points, and a high compliance 
level – from 81 to 120 score points.
Statistical processing of the results was carried out 
using Statistica 10 software package. The data are pre-
sented as M±σ. The results of the study were processed 
by nonparametric methods of statistical analysis using the 
Mann-Whitney test for independent samples and the Wil-
coxon test for dependent groups. Differences were consi-
dered significant at a significance level of p<0.05.
Results and discussion
The study involved 86 patients who underwent OLT in 
“Scientific and Research Institute – S.V. Ochapovsky 
Regional Clinical Hospital № 1” (main group 1) and 56 
patients with chronic diseases (control group 2). Three 
questionnaires from group 2 were rejected as they were 
not completed in full. Thus, 139 questionnaires were in-
cluded in the statistical analysis. The main causes of liver 
failure that required transplantation were viral hepatitis 
(60.5%), primary biliary cirrhosis (16.3%), autoimmune 
(9.3%) and toxic hepatitis (9.3%).
The mean age of the recipients was 50.3±8.6 years, 
with the proportion of men being 54.7%. The following 
compliance levels were identified in group 1: the gene-
ral level reached 95.8±9.4; the social level – 30.4±4.2; 
the emotional level – 33.3±3.7 and the behavioral level 
– 32.0±3.8. In group 2, the general compliance level was 
87.6±10.9; the social level – 28.8±4.8; the emotional le-
vel – 30.2±3.4 and the behavioral level – 28.6±3.9. Com-
pared to control group 2, group 1 had the higher complian-
ce levels, as follows: the general level – by 9% (p=0.01), 
the social level – by 5.6% (p=0.22), the emotional level 
– by 10.3% (p=0.01) and the behavioral level – by 11.9% 
(p=0.005). The absolute average scores and the distributi-
on of behavioral, emotional and social compliance levels 
in both groups are shown in Figure 2.
In the transplantation context, the idea of compliance 
is multifaceted. It may include compliance to drug the-
rapy, which involves not only taking immunosuppres-
sants, but also a number of clinical and pharmacologi-
cal groups of drugs prescribed to recipients, among the 
most frequent ones being antiviral drugs, antimicrobials, 
antifungal agents, anti-lipidemic drugs, insulin, oral hy-
poglycemic agents, and antihypertensive drugs. All these 
drugs are used to prevent or to treat both complications of 
immunosuppressive therapy and other factors that have 
a negative effect on transplant and recipient’s survival. 
Thus, according to the abovementioned, patients were not 
informed of which medication the survey questions were 
related to. 
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The present study used a questionnaire by R.V. Kadyrov 
“The Level of Compliance” (Kadyrov et al. 2014), which 
allows, unlike screening questionnaires, for example, by 
Morisky et al. (Morisky et al. 1986), to study the various 
components of compliance (emotional, social, behavioral).
The gender analysis of liver transplant recipients’ 
compliance in women and men showed the following 
results, respectively: the general compliance level was 
97.5±1.96 and 94.3±1.86 (p = 0.25), the social level was 
30.7±0.92 and 30.1±0.73 (p = 0.60); the emotional level 
was 34.1±0.82 and 32.7±0.82 (p = 0.23) and the behavi-
oral level was 32.7±0.86 and 31.5±0.72 (p = 0.32). The 
general compliance level in transplant recipients under 
50 years old was 93.5±6.8; the social level – 28.9±3.9; 
the emotional level – 33.6±2.9 and the behavioral level 
– 31.0±2.2. The comparison of liver recipients aged over 
and under 50 showed no significant differences. The fol-
lowing compliance levels were identified in patients over 
50: the general compliance level reached 95.7±9.4 (p = 
0.85); the social level – 30.1±4.2 (p = 0.76); the emoti-
onal level –33.5±3.7 (p = 0.30) and the behavioral level 
– 32.1±3.8 (p = 0.21).
It was determined that the liver transplant recipients 
had higher levels of general, behavioral and emotional 
compliance compared to the patients with chronic disea-
ses. Neither gender nor age differences in any types of 
compliances were identified. The great majority of the 
respondents showed the general compliance level within 
80 to 120 score point (on average exceeding 90 score 
point). This fact reflects a high level of compliance to the-
rapy and is consistent with the research by Berlakovich 
G.A. et al. (Berlakovich et al. 2000), which reports about 
3% of cases of patients’ non-compliance to clinical pres-
criptions. The authors relied on computerized observation 
protocols, but the idea of non-compliance was not clearly 
defined (Berlakovich et al. 2000). 
The facts of high compliance in liver transplant reci-
pients contrast with a number of foreign studies carried 
out over the past years. One of the first studies evaluating 
the prevalence of transplant recipients’ non-compliance 
to therapy was accomplished by Schweizer et al. in 1990 
(Schweizer et al. 1990), with the immunosuppression 
steroid regimens dominating. Three out of thirteen adult 
liver transplant recipients had 23% level of non-com-
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pliance to drug therapy, two of them died. One patient 
suffered from rejection episodes which occurred due to 
the low compliance, which was evaluated by the level of 
cyclosporine in the blood. The study conducted by O’-
Carroll et al. (O’Carroll et al. 2006) reported about 24% 
of the non-compliance cases in liver transplant recipients. 
The low compliance rate to immunosuppressive therapy 
reached 15%, according to the retrospective examinati-
on of the recipients in Scotland (Stilley et al. 2010). Ac-
cording to Burra P. et al., the rate of non-compliance to 
immunosuppressive therapy among adult liver transplant 
patients ranges from 15 to 40% (Burra et al. 2011).
Thus, in a number of transplant centers the opposite re-
sults were obtained. It can be explained by heterogeneity 
in the priorities for usage of different immunosuppressive 
regimens to prevent liver rejection. It is well-known that 
side effects from drugs are the risk factors causing low 
level of compliance (Drent et al. 2005, O’Carroll et al. 
2006, Rovelli et al. 1989, Schweizer et al. 1990).
The side effects from the inhibitor of calcineurin, cy-
closporine and glucocorticoids are most pronounced. 
Over the last several years, the administration of non-
steroid treatment regimens in many transplant centers has 
resulted in a decreased frequency of undesirable side ef-
fects and an improved subjective tolerance to treatment. 
Thus, patients are less concerned about the possible future 
issues with hormone therapy administration, which con-
tributes to better compliance to the recommended therapy. 
It can be assumed that the dramatic differences among the 
results of compliance evaluation in studies completed in 
different years are primarily caused by the significant pro-
gress in immunosuppressive regimens prescribed to liver 
transplant recipients, as they now almost completely ex-
clude usage of glucocorticoids.
Another important aspect of compliance evaluation, 
influencing the results and complicating the literature data 
comparison, is lack of an objective and accurate measure-
ment method. Many authors who research compliance in 
transplant recipients emphasize that nowadays there are 
both direct and indirect methods of assessment, but there 
is no gold standard for measuring compliance to drug the-
rapy; each method has its strengths and weaknesses (Dob-
bels et al. 2005, Hathaway et al. 1999, Laederach-Hof-
mann and Bunzel 2000).
The multidirectionality in assessing the results of 
compliance, revealed by a number of authors in different 
years, has led to the conclusion that only a multimodal 
approach based on several measurement methods is more 
sensitive and acceptable than usage of a single indicator 
(Drent et al. 2009, Quittner et al. 2008).
Consequently, further studies are to obtain facts by re-
lying not only on survey methods, which are subjective to 
some extent, but also on quantitative and objective methods 
of compliance assessment, such as determination of the con-
centration of drugs in the systemic blood, the count of tablets 
used, consideration of pharmacotherapy schemes applied, 
etc. Apart from that, in order to specify the disease prognosis 
in liver transplant recipients, it is necessary to break down 
compliance to drugs and general lifestyle recommendations. 
Non-compliance to immunosuppressive therapy increases 
the risk of transplant rejection and its potential loss, while 
non-compliance to general lifestyle recommendations (for 
example, avoiding alcohol and smoking after transplantati-
on) may lead to other complications, such as de novo tumour 
and an increase in the healthcare costs.
Conclusions
1. Liver transplant recipients have higher statistically 
significant (p <0.005–0.01) levels of general, behavi-
oral and emotional compliance compared to those in 
patients with chronic diseases.
2. There are no significant differences in the level of 
social compliance between the groups of liver trans-
plant recipients and the group of patients with chronic 
diseases.
3. The emotional and social compliance levels in liver 
transplant patients were the most and the least pron-
ounced, respectively. 
4. Neither significant gender nor age differences in any 
types of compliance in the group of liver transplant 
recipients were identified.
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